<DOC>
	<DOCNO>NCT01086449</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity immunogenicity GSK Biologicals ' candidate Herpes Zoster ( HZ ) vaccine healthy ethnic Japanese adult .</brief_summary>
	<brief_title>Safety Immunogenicity GSK Biologicals ' Herpes Zoster Vaccine 1437173A Healthy Ethnic Japanese Adults</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol ( e.g . completion diary card , return followup visit ) . A male female , include , 18 30 year age time first vaccination inclusion young adult cohort age , include , 50 69 year age time first vaccination inclusion old adult cohort . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . Japanese ethnic origin ( define born Japan four ethnic Japanese grandparent able speak Japanese ) . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Male subject may enrol study , subject : agreed practice adequate contraception ( 2 month completion vaccination series ) . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine/product , plan use study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior first vaccine/product dose . For corticosteroid , mean prednisone &gt; = 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Concurrent plan participation another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Immunosuppression result haematopoietic stem cell transplantation , AIDS symptomatic HIV infection . Previous vaccination HZ ( either register product investigational product participation HZ vaccine study ) . History HZ . History allergic disease reaction likely exacerbated component vaccine . Receipt immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Receipt immunisation within one month first study vaccination ( 2 week case inactivate influenza vaccine nonreplicating immunisation product [ e.g. , tetanus reduce dose diphtheria toxoid ( dT ) vaccine , pneumococcal vaccine , hepatitis A vaccine , hepatitis B vaccine ] ) , schedule within 30 day study vaccination . Acute disease and/or fever time enrolment . Fever define temperature &gt; = 37.5°C ( 99.5°F ) axillary setting ; Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution ( child bear potential ) . Male plan father child planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>safety</keyword>
	<keyword>Japanese</keyword>
	<keyword>Herpes Zoster</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>Herpes Zoster healthy ethnic Japanese adult</keyword>
	<keyword>Vaccine</keyword>
</DOC>